|
|
Factsheet as on February 28, 2025 |
Factsheet as on February 28, 2025
Structure
Open Ended
Fund Category
Thematic/Sectoral
Fund Manager
Sailesh Raj Bhan
Exit Load
Within 1 Month - 1%
Fund Size
Rs 7637 crs
Launch Date
June 05, 2004
Investment Objective
To generate consistent returns by investing in equity or fixed income securities of pharma and other associated companies.
Market Cap Allocation
Scheme Performance
| 1 Year | 2 Years | 3 Years | 5 Years | |
| Scheme (%) | 4.91 | 30.10 | 17.37 | 23.71 |
| Nifty 500 (%) | -0.69 | 16.99 | 11.58 | 16.55 |
Top 10 Holdings
| Company Name | % of Assets |
| Sun Pharmaceutical Industries | 13.7 |
| Divi Laboratories | 9.3 |
| Lupin | 7.7 |
| Cipla | 5.9 |
| Dr Reddys Laboratories | 5.4 |
| Apollo Hospitals Enterprise | 5.1 |
| Abbott India | 3.8 |
| Vijaya Diagnostic Centre | 3.4 |
| Medplus Health Services | 3.4 |
| Glaxo Smithkline Pharmaceuticals | 3.3 |
Year On Year Performance (Scheme V/S Nifty 500)
Ratios:
| Standard Deviation | 15.62 |
| Information Ratio | 0.14 |
| Beta | 0.79 |
| Sharpe Ratio | 0.19 |
Top 10 Sectoral Holdings (%)
SIP Returns
Source: MFI Explorer, Bloomberg.
Please refer to the disclaimer and glossaries
Kotak Mahindra Bank Limited, AMFI Registered Mutual Fund Distributor, ARN 1390
Kotak Mahindra Bank Limited, AMFI Registered Mutual Fund Distributor, ARN 1390